5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
There are no Transcripts on FPRX.
GlobeNewswire (Mar 5, 2014)
GlobeNewswire (Feb 12, 2014)
GlobeNewswire (Feb 10, 2014)
GlobeNewswire (Feb 6, 2014)
GlobeNewswire (Feb 3, 2014)
GlobeNewswire (Jan 9, 2014)
FPRX vs. ETF Alternatives
Monday, Feb 2412:48 PM|Monday, Feb 2412:48 PM| 1 Comment
Friday, Feb 79:10 AM|Friday, Feb 79:10 AM| Comment!
Thursday, Dec 122013, 12:52 PM|Thursday, Dec 122013, 12:52 PM| 3 Comments
Friday, Nov 12013, 12:47 PM
Monday, Oct 142013, 4:27 PM
Monday, Oct 142013, 4:27 PM| Comment!
- Analysts are out with a bevy of upbeat coverage initiations for Five Prime Therapeutics (FPRX).
- Jefferies: Buy, PT $20.
- Wells Fargo: Outperform, PT $18.
- Guggenheim: Buy, PT $20.
- BMO: Outperform, PT $24.
- Look for data from a Phase 1b trial of GSK-partnered FP-1039 (it's an FGF pathway inhibitor) late next year.